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| INTRODUC TI ON
In the last 10 years, based on further elucidation of the human immune system and cancer microenvironment, cancer immunotherapies have been established as new cancer treatments.
1 Notably, immune checkpoint inhibitor therapies provide adequate clinical effects in certain cases with malignant diseases. [2] [3] [4] [5] [6] Cytotoxic T lymphocytes (CTL) play an extremely important role in antitumor immunity through their ability to recognize and eliminate cancer cells. In addition, human lymphocyte antigen (HLA) class I molecules present tumor-specific antigens to CTL which have cancer cell recognition and killing functions. Therefore, it is important that HLA class I antigens are expressed on the target cell surface, to establish cancer-specific immune reactions and exert sufficient antitumor effects.
Previously, the loss or downregulation of HLA class I expression has been shown in advanced cancer cells to be one reason for their escape from immune surveillance systems. 7 Indeed, histological evidence and molecular mechanisms for the loss or downregulation of HLA class I expression have been reported for several types of cancers, including breast, gastric, bladder and renal cancers. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In addition, some studies have suggested that the HLA class I expression could be closely related to the prognosis of patients who have solid cancers. 9, [19] [20] [21] [22] [23] [24] However, the rates of Human lymphocyte antigen class I molecules contain classical HLA-A, -B and -C and non-classical HLA-E, -F and -G antigens, which are transmembrane glycoproteins with a non-polymorphic 12-kDa β2-microglobulin light chain and a polymorphic 45-kDa heavy chain. 25 Previous anti-HLA class I monoclonal antibodies, including HC-A2 and HC-10, cannot recognize all HLA types. Moreover, W6/32 recognize an allele-specific native structure of HLA class I molecules. Therefore, the previously mentioned anti-HLA class I antibodies would not be ideal for formalin-fixed paraffin-embedded tissues that have denatured HLA class I molecules. By contrast, EMR 8-5, a novel pan HLA monoclonal antibody, is suitable for HLA class I immunostaining in formalin-fixed paraffin-embedded tissue specimens that have been treated for long-term preservation. Indeed, the expression of HLA class I has been histologically examined using EMR 8-5 in colorectal, 23 breast, 8, 14 osteosarcoma, 9 renal 20,24 and non-small cell lung cancers.
15
In this study, we compared HLA class I expression levels in can- 
| MATERIAL S AND ME THODS

| Patients and tissue samples
| Interferon-γ enzyme-linked immunospot assay
In cancer cells and surrounding non-tumorous hepatocytes from day intervals between stimulations. CD8 + cells were isolated using human CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) from these PBMC. CD8 + CD107a + cells were sorted using a FACSAria cell sorter. Sorted CTL were stimulated and the CTL clones were established as previously described. 27 Effector cells were incubated with target cells for 20 hours at 37°C in 5% CO 2 .
The BD ELISPOT set (BD Biosciences, San Jose, CA, USA) was used for an IFN-γ ELISPOT assay. The spot numbers that indicate a peptide-specific CTL response were automatically calculated using the Eliphoto system (Minerva Tech, Tokyo, Japan).
| Statistical analysis
Comparison of the HLA class I expression by EMR 8-5 between cancer cells and surrounding non-tumorous hepatocytes in enrolled HCC patients was conducted using the Mann-Whitney Utest. Clinical prognosis, including RFS and OS, was evaluated using the Kaplan-Meier analysis, and the differences between 2 groups were compared using the log-rank test. RFS and OS were calculated from the date of surgery to the date of recurrence and death, respectively, or the date of last follow up if there were none of these events. In addition, association between the HLA class I expression level in cancer cells and tumor volume in HCC patients was evaluated using Pearson's correlation coefficient. Differences were considered significant at P < 0.05. All analyses were conducted using R version 3.5.1.
| RE SULTS
| Clinical characteristics of enrolled patients with hepatocellular carcinoma
Patient characteristics are shown in Table 1 . The mean age of enrolled patients was 58.6 years (range: 25-85 years); these patients included 13 men and 7 women. In addition, 17 and 3 patients had PS 0 and 1, respectively, and there were no patients with PS ≥2. In addition, 5 patients had hepatitis B and 9 had hepatitis C virus infections. Figure 1E,F 
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hepatocytes using an IFN-γ ELISPOT assay (Figure 3) . The results suggested that peptide-pulsed cancer cells had strong reactivity with peptide-specific CTL, with an increase in the IFN-γ spot numbers ( Figure 3A) . In contrast, peptide-pulsed surrounding non-tumorous hepatocytes were poorly reactive with specific CTL, and showed little increase in the IFN-γ spot numbers. In addition, we found that in cancer cells, the immunological reactivity with peptide-specific CTL became stronger as the concentration of peptide-specific CTL increased ( Figure 3B ). These differences in immune response of peptide-specific CTL between cancer cells and non-tumorous hepatocytes might be related to differences in the HLA class I expression level. In addition, based on these results, peptide-specific CTL might not attack surrounding normal tissue, even if injected peptides spread to the surrounding nontumorous lesions beyond the tumor area in intratumoral peptide injection therapy, which has been previously reported. 
| Expression level of human lymphocyte antigen class I in cancer and surrounding normal tissue cells in various types of solid cancers
We also compared the HLA class I expression level by EMR 8-5 in cancer cells and surrounding normal tissue cells with several other solid cancers, including pancreatic, gallbladder, esophageal, colon and breast cancers (Table S1 ). The results are summarized in Table 2 and representative images are shown in Figure 5 . In these tumorous sites, the cell membranes of many cancer cells were stained 
| D ISCUSS I ON
In this study, we evaluated the HLA class I expression level in cancer cells and surrounding non-tumorous hepatocytes in stage I-II HCC patients who underwent radical surgery, by immunohistochemistry using EMR 8-5. We showed that in 15 of 20 HCC patients (75%), the expression levels of HLA class I were higher in cancer cells than who possess these HLA molecules. 9 We believe that EMR 8-5 is an ideal antibody for evaluating the expression of HLA class I antigen in HCC patients.
Previously, it has been reported that HLA class I expression is downregulated in various cancer cells, including sarcoma (70%), 9 and gastric (45%), 16 non-small cell lung (30%) 15 and esophageal (60%) 17 cancer, by immunohistochemistry using EMR 8-5. Human lymphocyte antigen class I molecules play an important role in anti-cancer immune systems, especially as molecules with the ability to present antigen-specific CTL. 14 In this study, we demonstrated that antigen-specific CTL had high reactivity toward HCC cells with strongly positive HLA class I expression (Figure 3 ).
Previously, we identified glypican-3 (GPC3), which is a tumor-associated antigen, and conducted clinical trials of GPC3-peptide vaccination against patients with several cancer types, including advanced HCC. 26, [39] [40] [41] [42] [43] As a result of these trials, we found an adequate anti-tumor effect in advanced HCC with this peptide vaccination, which led to a better OS in HCC patients. 26, 39 We also developed a method of immunotherapy using intratumoral peptide injection that could induce additional peptide loading onto tumor cells. We demonstrated that this therapy enhanced the invasion of peptide-specific CTL into the tumor site in a mouse model. come. In this study, the RFS and OS of the "complete positive" group tended to be better than those of "incomplete positive and negative" groups, during 1.5-5 and >5 years after surgery, respectively.
